Practical Recommendations for COPD:

Slides:

Advertisements

Similar presentations

PREVENTING COPD EXACERBATIONS

Advertisements

Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

내과 R2 이지훈 N Engl J Med Sep 8.

Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.

Analysis of chronic obstructive pulomnary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):

1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.

GOLD 2017 major revision: Summary of key changes

Thank you for viewing this presentation.

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE):

Upfront Combination Therapy vs Step-Up Approach for PAH:

Dr. Kevin Gruffydd-Jones Box Surgery, Wiltshire, England

COPD Report 5 Coles Lane, Oakington, Cambridge, CB24 3BA.

COPD By Alaina Darby.

Volume 149, Issue 5, Pages (May 2016)

Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.

COPD by the Guidelines.

Monitoring and Modifying Treatment in PAH

This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

Treatment Strategies in Mild to Moderate COPD

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

Highlights From the Inaugural COPD7USA Conference: Focus on Treatment Challenges in COPD.

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Optimizing Therapy for Osteoarthritis

UNDERSTANDING RISK STRATIFICATION IN PAH:

Modern Strategies for Basal Insulin Use in T2D

Stepping Up Asthma Control for Effective Management

Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.

Managing Hereditary Angioedema

What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?

Volume 153, Issue 4, Pages (April 2018)

When Would You Use Single Inhaler Triple Therapy in COPD?

Combination Inhaled Therapy in COPD: The Impact of Recent Data

Updates in Pulmonary Arterial Hypertension

Is RA Treatment Addressing the Real Needs of Patients?

Personalizing Statin Therapy in Patients With HIV

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Therapeutic Strategies in COPD Focus on Patient Characteristics and Drug Delivery.

A Primer on Medication Delivery Systems in COPD Management

The Importance of Getting the Dose Right in HF

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Volume 152, Issue 6, Pages (December 2017)

A Primer on Medication Delivery Systems in COPD Management

What's New in Therapeutic Options for Moderate to Severe RA?

Cancer-Associated Thrombosis

Long-Acting Agents in Severe COPD

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Personalizing COPD Therapy According to Recent Clinical Trial Evidence

Oral Prostacyclin Pathway Agents in PAH

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Patient Stories in PAH: Sequential Therapy in a FC II Patient

The Changing Goals of CML Therapy

Moderate-to-severe exacerbations for patients who experienced an exacerbation in the past year Network meta-analysis results for treatments compared with.

PAH Pathways: What Do the Data Tell Us?”

Binge Eating Disorder.

Merging the Art and Science of Managing nOH in Clinical Practice

Prescribing Update - Respiratory July 2019

Practical Recommendations for COPD:

Targeted Care for COPD.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Agenda. Diagnosis, Assessment, and Treatment of the COPD Patient in Primary Care.

Foundations of Asthma.

Presentation transcript:

Practical Recommendations for COPD:

The Burden of COPD

The ABCD Assessment Tool

GOLD 2017: New Pharmacological Treatment Recommendations

Indacaterol/Glycopyrronium vs Monocomponents and Placebo in Patients With COPD

SPARK: Indacaterol/Glycopyrronium vs Glycopyrronium and Tiotropium

Exacerbation Rates With Salmeterol/Fluticasone Combination and Tiotropium: INSPIRE Study

Indacaterol/Glycopyrronium vs Salmeterol-Fluticasone in the ILLUMINATE Study

Effect of Indacaterol/Glycopyrronium on FEV1 AUC0−12h at Week 26 in Subgroups

TDI Focal Score at Weeks 12 and 26

SGRQ Total Score at Week 26

Indacaterol/Glycopyrronium vs Salmeterol-Fluticasone Effect on Trough FEV1

Indacaterol/Glycopyrronium Significantly Increased Time to First Moderate or Severe COPD Exacerbation vs SFC

Reduced Exacerbations With Indacaterol/Glycopyrronium vs SFC in Patients With an Exacerbation in the Previous Year

Effect of ICS on Preventing COPD Exacerbations

Use of ICS and Risk for Pneumonia: Dose-Response Relationship

WISDOM: ICS Withdrawal Did Not Increase the Exacerbations in Patients With Severe COPD

GOLD 2017: New Pharmacological Treatment Recommendations (cont)

GOLD 2017: Recommendations in Groups C and D

Risk Factors for Pneumonia on ICS

Reported Pneumonia in Patients With COPD: Findings From the INSPIRE Study

Patients Without an Indication for ICS

Practical Recommendations for ICS Withdrawal/Reduction

GOLD 2017: Treatment Recommendations in Group D

Use of ICS and Risk for Pneumonia: Dose-Response Relationship (cont)

Available Therapies for COPD

Current Concepts in Targeting COPD Pharmacotherapy

Conclusion

Abbreviations

Abbreviations (cont)